CSF biomarkers in posterior cortical atrophy

Neurology

Volumn 76, Issue 21, 2011, Pages 1782-1788

  Seguin, J ^a,k,l,m,n,o   Formaglio, M ^b,k,l   Perret Liaudet, A ^a,k   Quadrio, I ^a,k,l   Tholance, Y ^a,k,l   Rouaud, O ^d   Thomas Anterion, C ^e   Croisile, B ^b,k   Mollion, H ^b,k   Moreaud, O ^f   Salzmann, M ^g   Dorey, A ^a,k   Bataillard, M ^h   Coste, M H ^i,k   Vighetto, A ^b,c,k,l   Krolak Salmon, P ^{b,j,k,l,m,n,o}  

^a Centre de Biologie et de Pathologie Est   (France)

^b Department of Neurology ^*  (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER DE ROANNE   (France)

^h Centre Hospitalier Belfort   (France)

ⁱ Pierre Garraud Hospital   (France)

^j Hopital des Charpennes CHU de Lyon   (France)

^k Center for Memory Resources and Research   (France)

^l UNIVERSITÉ LYON 1   (France)

^m INSERM   (France)

ⁿ CNRS   (France)

^o LYON NEUROSCIENCE RESEARCH CENTER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MALE; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; POSTERIOR CORTICAL ATROPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VISUAL DISORDER;

EID: 79958105092     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821ccc98     Document Type: Article

References (36)

1. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol 1988;45:789-793.
2. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDGPET. J Neurol Neurosurg Psychiatry 2003;74:1521-1529.
3. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168-1174. (Pubitemid 39350012)
4. Renner JA, Burns JM, Hou CE, McKeel DW Jr, Storandt M, Morris JC. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 2004;63:1175-1180. (Pubitemid 39350013)
5. Hof PR, Archin N, Osmand AP, et al. Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report. Acta Neuropathol 1993;86:215-223. (Pubitemid 23275938)
6. Berthier ML, Leiguarda R, Starkstein SE, Sevlever G, Taratuto AL. Alzheimer's disease in a patient with posterior cortical atrophy. J Neurol Neurosurg Psychiatry 1991; 54:1110-1111.
7. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007;130:2636-2645. (Pubitemid 47511719)
8. Tang-Wai DF, Josephs KA, Boeve BF, Dickson DW, Parisi JE, Petersen RC. Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology 2003;61:1134-1135. (Pubitemid 37461954)
9. Wiltfang J, Lewczuk P, Riederer P, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005;6:69-84. (Pubitemid 40895131)
10. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 2003;4:147-155.
11. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143-1153. (Pubitemid 32405708)
12. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease: The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-116.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Der Linder V, Coyette F, Poitrenaud J, et al. l'É preuve De Rappel Libre/Rappel Indicé à 16 Items (RL/RI-16): l'É valuation des Troubles De la Mémoire. Marseille, France: Solal; 2004.
15. Delis DC, Freeland J, Kramer JH, Kaplan E. Integrating clinical assessment with cognitive neuroscience: construct validation of the California Verbal Learning Test. J Consult Clin Psychol 1988;56:123-130.
16. Wechsler D. Echelle Clinique De Mémoire De Wechsler, 3ed ed. Paris: ECPA; 2001.
17. Rapport LJ, Millis SR, Bonello PJ. Validation of the Warrington theory of visual processing and the Visual Object and Space Perception Battery. J Clin Exp Neuropsychol 1998;20:211-220. (Pubitemid 28451700)
18. Benton AL, Hamsher KD, Varney NR, Spreen O. Contributions to Neuropsychological Assessment: A Clinical Manual. New York: Oxford University Press; 1983.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-944. (Pubitemid 14076461)
20. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872. (Pubitemid 43970103)
21. Clinical and neuropathological criteria for frontotemporal dementia: The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994;57:416-418.
22. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234. (Pubitemid 43238346)
23. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
24. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.
25. Engelborghs S, De Vreese K, Van De Casteele T, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008;29: 1143-1159. (Pubitemid 351822410)
26. Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech Ageing Dev 2006;127:129-132. (Pubitemid 43165611)
27. Kambe T, Motoi Y, Ishii K, Hattori N. Posterior cortical atrophy with [(11)C] Pittsburgh compound B accumulation in the primary visual cortex. J Neurol 2010;257:469-471.
28. Baumann TP, Duyar H, Sollberger M, et al. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 2010;29:530-533.
29. De Souza LC, Lamari F, Belliard S, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry Epub 2010.
30. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006;67:637-643. (Pubitemid 44273611)
31. Van Der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009;72:1056-1061.
32. Iqbal K, Flory M, Khatoon S, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005;58:748-757. (Pubitemid 41552550)
33. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsyconfirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 2009;55: 214-218.
34. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010;45:30-40.
35. Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53:795-800. (Pubitemid 29448302)
36. Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010;133:2045-2057.